Streetbeat News

FBRX

Forte Biosciences, Inc.

https://www.fortebiorx.com

Industry

Biotechnology

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Trading for FBRX was halted at 7:50:00 p.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released soon, which could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:50 pm

Chardan Capital has reiterated its Buy rating for Forte Biosciences, maintaining a price target of $3. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:33 pm

Forte Biosciences shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 7:59 pm

Forte Biosciences (NASDAQ:FBRX) reported a Q2 EPS loss of $(0.27), missing the analyst consensus estimate of $(0.17) by 58.82%. This represents a 35.71% improvement over the $(0.42) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:17 pm

Brookline Capital has initiated coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and set a price target of $4.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 9:56 am

Forte Biosciences reported a Q1 GAAP EPS of $(0.16), surpassing the estimated $(0.17).

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 9:12 pm

Forte Biosciences reported a Q1 2024 GAAP EPS of $(0.32), missing the consensus estimate of $(0.17) by 88.24%.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 8:22 pm

Ladenburg Thalmann analyst Michael Higgins upgrades Forte Biosciences (FBRX) from Neutral to Buy and sets a price target of $2.75.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 9:36 pm

Forte Biosciences, Inc. reported an increase in its 2023 EPS loss to $(1.00) from $(0.80) YoY. R&D expenses rose to $21.9 million, driven by manufacturing, preclinical, and clinical expenses, notably for the FB-102 program. G&A expenses also increased to $10.6 million due to higher professional and legal costs. The company ended the year with $37.1 million in cash and 36.3 million shares outstanding.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:13 pm

Funicular Funds reported in an amended 13D filing that Forte Biosciences filed a legal action against Jacob Ma-Weaver and Funicular Funds on Oct 28, 2023. Funicular Funds, which holds a 5.59% stake in Forte Biosciences, believes the allegations are baseless and without merit.

Portfolio Pulse from Charles Gross

January 09, 2024 | 11:20 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.